Cosmos Health’s CosmoFarm Reports Q2 Revenue Of Over $15M, $60M Annualized Run Rate; Says Robotics, Automation And AI-Enabled Systems Across Procurement, Inventory And Order Execution, With Capacity That Could Support A Further $40M Or More In Annual Revenue, Which Would Provide Infrastructure For Annualized Revenue Above $100M

Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date Pharmacies served daily up 3.6x, from ~100 in 2017 to ~360 today, within a total network of more than 1,500 pharmacies Operating leverage from enhanced route density and optimized order execution - during 2025, revenue per customer up 12%, profitability per customer up 14% and the active customer base up 20% Robotics, automation and AI-enabled systems across procurement, inventory and order execution, with capacity that could support a further $40 million or more in annual revenue, which would provide infrastructure for annualized revenue above $100 million Instrumental to the Company's 2029 guidance of $200.6 million in revenue, $71.2 million in gross profit, $44.2 million in adjusted EBITDA and $31.0